Year: 2017
Type: article
Abstract: acetylation (H3-Ac) was measured by flow in total CD3+ T-cells pre-infusion; hrs 12, 24, 48; days 7, 14, 28.RMD was measured preand post-infusion; hrs 4, 6, 12, 24.Pre-specified primary comparisons were between the pooled RMD and pooled placebo groups using the Wilcoxon test.Results: 43 enrolled (36 RMD; 7 placebo).All completed the infusions.Median RMD levels at hr 4 were 12.0, 75.2, 89.0 ng/mL in the 0.5, 2.5 and 5 mg/m 2 cohorts.The primary efficacy measure of SCA change from pre-infusion to the average of 24 and 48 hr post was similar between the pooled RMD and placebos (median: 0.12 vs. 0.12 log10 cps/mL, p=0.88, [95% CI on difference: -0.48, 0.33]).No significant increases in any virologic measure or in H3-Ac were observed (p > 0.05).Conclusions: Single RMD doses were well-tolerated but did not increase HIV expression OR H3-Ac.PP 6.0
Source: Journal of Virus Eradication
Institution: University of California, San Francisco
Language: English
Topic: HIV Research and Treatment
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,950
OpenAlex ID: W3041660602
